{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Stringent Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Very good Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Partial Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"OR is defined as a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IMWG Criteria: sCR: CR (negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow); normal free light chain (FLC) ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis/\\>= 90% reduction in serum M-protein and urine M-protein level \\< 100 mg/24 hours; PR: \\>= 50% reduction of serum M-Protein and reduction in urinary M-protein by \\>= 90%/to \\< 200 mg/24 hours. In addition to the above, if present at baseline a \\>= 50% reduction in the size of soft tissue plasmacytomas is also required.","groups":[{"description":"Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) until disease progression.","id":"OG000","title":"M3258 10 mg QD"},{"description":"Participants received M3258 at a dose of 10 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"OG001","title":"M3258 10 mg Twice Per Week"},{"description":"Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"OG002","title":"M3258 20 mg Twice Per Week"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants who were administered any dose of the trial medication.","reportingStatus":"POSTED","timeFrame":"Time from first dose of study treatment up to 18.2 months","title":"Part A: Number of Participants With Overall Response (OR) as Assessed by Investigator Using International Myeloma Working Group (IMWG) Criteria","type":"SECONDARY","unitOfMeasure":"Participants"}